Connect with us

American Cannabis News

Trulieve Q4 Revenue Falls 3% – New Cannabis Ventures

Published

on

Trulieve Q4 Revenue Falls 3% – New Cannabis Ventures

Trulieve reports 2025 Q4 and full-year results with 60% gross margin and record cash flow generation
  • Full year revenue of $1.2 billion with a gross margin of 60%
  • 2025 record cash flow from operations of $273 million and free cash flow of $229 million*
  • A record 50.1 million branded products sold in 2025, up 5% from last year

TALLAHASSEE, Fla., Feb. 26, 2026 /PRNewswire/ — Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “The Company”), the leading and top performing cannabis company in the United States, today announced its results for the fourth quarter and full year ended December 31, 2025. Numbers may not add up perfectly due to rounding.

2025 Full Year Financial and Operating Highlights*

  • Revenue is $1.2 billion with 94% of revenue coming from retail.
  • Achieved 60% gross margin, with GAAP gross profit of $711 million.
  • A net loss attributable to common stockholders of $116 million was reported. Adjusted net loss of $27 million excludes non-recurring charges, asset impairments, disposals and discontinued operations.
  • Achieved record adjusted EBITDA of $427 million*, or 36% of revenue, up $7 million, or 2%, from 2024.
  • Generated record cash flow from operations of $273 million and free cash flow of $229 million*.
  • The cash amount at the end of the year was 256 million dollars.
  • Repaid $368 million of senior secured notes and repaid $15.8 million of mortgages in 2026.
  • Private placement of $140 million of senior secured notes due 2030.
  • Conditional approval granted for a Distributorship license under the Texas Compassionate Use Program.
  • Grown the rewards program to 915,000 members as of December 31, 2025.
  • 11 dispensaries were added in 2025, with 233 retail locations nationwide at the end of the year.

*See “Non-GAAP Financial Measures” below for additional information and reconciliations to GAAP for all non-GAAP measures.

Q4 2025 Financial and Operating Highlights*

  • Revenue was $293 million, with 93% of revenue coming from retail.
  • Achieved 60% gross margin, with GAAP gross profit of $175 million.
  • A net loss attributable to common stockholders of $43 million was reported. Adjusted net loss of $3 million excludes non-recurring charges, asset impairments, disposals and discontinued operations.
  • Achieved adjusted EBITDA of $105 million* or 36% of revenue.
  • Cash flow from operations of $59 million and free cash flow of $56 million*.
  • A new mobile app serving Florida customers has been released, enabling patients to browse and reserve products, view promotions and check reward status in a seamless digital experience.
  • Opened one dispensary in Findlay, Ohio.

*See “Non-GAAP Financial Measures” below for additional information and reconciliations to GAAP for all non-GAAP measures.

Recent developments

  • Opened one dispensary in Fort Myers, Florida.
  • Closed second tranche of $60 million private placement of senior secured notes due 2030.
  • There are currently 234 retail dispensaries and more than four million square feet of processing and processing capacity in the United States.

Management Commentary

“We finished the year strong, winning a conditional license in Texas and repositioning our debt,” said Trulieve CEO Kim Rivers. “With a re-planning on the horizon, Trulieve is driving its momentum through 2026, prioritizing expanded reach, loyal customers, branded products and growth initiatives.”

Original press release

Published by NCV Newswire

NCV Newswire

New Cannabis Ventures’ NCV Newswire aims to gather high-quality content and information about leading cannabis companies to help our readers filter through the noise and stay on top of the most important cannabis business news. The NCV Newswire is edited by an editor and, however, is not automated. Got a secret news tip? Get in touch.

Get our Sunday newsletter





aawh

Michigan Cannabis Sales Fell Yet Again – New Cannabis Ventures

Published

on

By

Michigan Cannabis Sales Fell Yet Again – New Cannabis Ventures

Michigan April hemp sale decreased compared to a year ago, as they increased sequentially by 1.2%. At $258.6 million, sales decreased by 4.3 percent compared to last year.

Michigan’s cannabis regulatory agency breaks down sales by medical and adult use, with medical sales down 24.1% year-over-year to $0.4 million, down 5.6% sequentially, and adult-use sales down 4.3% year-over-year to $255.5 million, despite a one-day increase of 1.2% in March.

The state breaks down sales by category and provides pricing details by category for both medical and adult;

For Adults - Use
For Adults – Use
Medical

As supply continues to expand, adult flower prices have fallen sharply, although the decline is slowing. April’s average price of $945 per pound fell 4.2% sequentially to just above December’s record low and down 5.1% from a year ago.

Michigan hemp sales are expected to grow 82.1% to $1.79 billion in 2021, 27.9% to $2.29 billion in 2022, and 33.3% to $3.06 billion in 2023. billion In 2026, Michigan cannabis sales decreased by 5.9%.

Alan Brochstein, CFA

Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El

Get our Sunday newsletter





Continue Reading

280E

Cannabis Stocks Are Going Nowhere Quickly – New Cannabis Ventures

Published

on

By

Cannabis Stocks Are Going Nowhere Quickly – New Cannabis Ventures

You are reading this week’s edition of New Cannabis Ventures, a weekly magazine we have published since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve, as well as links to the most important news of the week. We no longer email them like we used to, but post this and all newsletters on our website here.

friends,

The New Cannabis Ventures Global Cannabis Stock Index edged up slightly in May, rising 1.1% to 5.76. Compared to the previous year, it decreased by 12.6%. The index, recalculated as of the end of the first quarter, is up 9.9% so far in the second quarter, lagging the S&P 500’s 12.8% gain. Here are the earnings of the 23 names currently in the index (SMG was dropped in late April after the sale of Hawthorne Gardening):

MSOs are very much higher as the rally approaches the discussion of the big transformation announcements on 4/22 and beyond. There are currently six MSOs and two of them have been promoted. The rest rose, and the average of the six was 38.1%. The AdvisorShares Pure US Cannabis ETF ( MSOS ) has rallied 48.5% since the end of March and is now up 11.7% year-to-date in 2026. Both GCSI names have fallen sharply, and the index has a total of seven double-digit gains in Q2, with six MSOs and Canopy holding investments. 14 of the 23 names returned less than GCSI.

As readers are probably aware, the US reclassified medical cannabis from Schedule I to Schedule III on 4/23, and that will go away. 280E tax for some of the businesses of cannabis companies. The Department of Justice will hold a hearing in late June to determine possible rezoning for adult use. If it passes, all 280E taxation will end, which is a good thing for cannabis companies and their investors, as well as the subsidiaries that serve them. It is not yet known what the outcome will be, and it is not yet known how past 280E taxes that have not been paid but are carried as liabilities (and not debt) will be handled. Also, there is no conclusion yet on SECURITY banking or the possibility of a raise.

NCV has stopped publishing news, although we continue to update the financial calendar as well as the earnings rankings. After more than 10 years with NCV and more than a dozen years with 420 Investor, I am in the process of moving on. I’ve appreciated sharing the news and my views here, and I want to wish everyone the best. Hopefully, the 280E taxation will end and the bear market that started in early 2021 for the hemp sector will come to an end.

Sincerely,

Alan:


This week’s newsletter is sponsored by the Paul E. Saperstein Co.

Massachusetts hemp production equipment for sale

On May 12, Middlesex Integrative Medicine, Inc.’s equipment is being auctioned online in Leominster, Massachusetts at 10:00 a.m. ET. All applications must be submitted online. Learn more Of the secured party’s sale of all assets of this cultivation equipment.

Interested parties may contact Paul Cotto at 617-227-6553 or email pcotto@pesco.com:.


New Cannabis Ventures publishes curated articles as well as exclusive news. Here is what we have published in the last 2 weeks.

Exclusives

Sales of Canadian hemp continued in February

View: Public Hemp Company Revenue and Earnings Trackingwhich ranks the highest-earning hemp stocks.

Stay on top of the most important communications from public companies by watching what’s coming cannabis investor calendar.

Alan Brochstein, CFA

Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El

Get our Sunday newsletter





Continue Reading

ACB

Few Care About This Large Cannabis Operator – New Cannabis Ventures

Published

on

By

Few Care About This Large Cannabis Operator – New Cannabis Ventures

You are reading this week’s edition of New Cannabis Ventures, a weekly magazine we have published since October 2015. The newsletter includes unique insight to help our readers stay ahead of the curve, as well as links to the most important news of the week. We no longer email them like we used to, but post this and all newsletters on our website here.

friends,

Just before Christmas, this newsletter discussed how Vireo Growth is getting pretty big. At the end of January I profiled how Vireo Growth is expanding its business. This week’s newsletters include six articles we’ve run since April 2, and Vireo Growth is central to two of them. Vireo Growth is big and getting bigger, but few people seem to care.

I’m not writing this to tell readers to care. In fact, while I used to include the company on my Focus List at 420 Investor, I no longer do. Earlier this month I wrote an article for my subscribers about why I keep looking at things but not including stocks in my Focus List. Here is the summary.

I watch VREOF because it is now one of the largest MSOs by revenue, but it continues to fall short of joining the Global Hemp Stock Index due to its low trading volumes. Average daily trading volume over the past month was 251,000 shares, which is about $100,000 in daily trading value. This is well below peers. Perhaps more importantly, the current price of $0.45, which is down 26.6% year-to-date, is significantly lower than the price of $0.625 for the last large cap in 2024. Not only are the investors not winning, but VREOF hsa distributed a lot of shares to the sellers and they are also under water.

Maybe Vireo Growth shares will reward their owners, or maybe it will continue to do so. I think hemp stock investors and debt holders should be asking why no one is thinking of this yet. Scotts Miracle-Gro, which has been public since 1992 and has a market cap of $3.6 billion, picked up much of VREOF’s stock when it spun off Hawthorne. The 213 million shares are “at an implied price of $0.60” per share, although VREOF hasn’t traded at $0.60 since January. When the divestiture was announced in late January, Vireo Growth closed at $0.5553.

So a large MSO that has reshuffled its management, is now in multiple markets, and has executed its plan to get bigger with several acquisitions, is still not responding to the cannabis investment community. I wish them the best.

Sincerely,

Alan:


New Cannabis Ventures publishes curated articles as well as exclusive news. Here is what we have published in the last 2 weeks.

Exclusives

The sale of hemp did not succeed until March

Michigan’s hemp sales are down again

Mergers and acquisitions

Aurora Cannabis acquires Cultivator for C$26.5 million

Greenhouse Brands and Vireo Growth Weak in California Cannabis Combination

Organigram Global Closes European Acquisition

Vireo Growth acquires Hawthorne Gardening Company

Follow Alan for real-time updates X.com:. Share and discover industry news with like-minded people on the largest group of cannabis investors and entrepreneurs LinkedIn:.

View: Public Hemp Company Revenue and Earnings Trackingwhich ranks the highest-earning hemp stocks.

Stay on top of the most important communications from public companies by watching what’s coming cannabis investor calendar.

Alan Brochstein, CFA

Based in Houston, Alan leverages his experience as an online community founder 420 Investorthe first and still the largest due diligence platform focused on publicly traded stocks in the cannabis industry. With his extensive network in the cannabis community, Alan continues to find new ways to connect the industry and facilitate its sustainable growth. time New Cannabis Ventureshe is responsible for content development and strategic alliances. Before turning his attention to the cannabis industry in early 2013, Alan, who began his career on Wall Street in 1986, worked as an independent research analyst with more than two decades of research and portfolio management experience. A prolific writer, with over 650 articles published since 2007 Looking for Alphawhere he has 70,000 followers, Alan is a frequent speaker at industry conferences and frequent source Media including the NY Times, Wall Street Journal, Fox Business and Bloomberg TV. Contact Alan. Twitter: |: Facebook |: LinkedIn: |: El

Get our Sunday newsletter





Continue Reading
Advertisement

Trending

Copyright © 2021 The Art of MaryJane Media